Oxaliplatin induced-neuropathy in digestive tumors

被引：58

作者：

Sereno, Maria ^{[1
]}

Gutierrez-Gutierrez, Gerardo ^{[2
]}

Gomez-Raposo, Cesar ^{[1
]}

Lopez-Gomez, Miriam ^{[1
]}

Merino-Salvador, Maria ^{[1
]}

Zambrana Tebar, Francisco ^{[1
]}

Rodriguez-Antona, Cristina ^{[3
]}

Casado, Enrique ^{[1
]}

机构：

[1] Infanta Sofia Univ Hosp, Dept Med Oncol, Madrid 28702, Spain

[2] Infanta Sofia Univ Hosp, Dept Neurol, Neuromuscular Unit, Madrid 28702, Spain

[3] Natl Ctr Oncol Res, Madrid 28015, Spain

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2014年 / 89卷 / 01期

关键词：

Oxaliplatin; Peripheral neuropathy; Digestive tumors; INDUCED PERIPHERAL NEUROPATHY; PHASE-II TRIAL; SIMPLIFIED BIMONTHLY LEUCOVORIN; COLORECTAL-CANCER; ADVANCED ADENOCARCINOMA; 5-FLUOROURACIL REGIMEN; 1ST-LINE TREATMENT; 2ND-LINE THERAPY; DOUBLE-BLIND; CHEMOTHERAPY;

D O I：

10.1016/j.critrevonc.2013.08.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Oxaliplatin is one of the main drugs used in digestive tumors treatment. Peripheral neuropathy is a well-recognized dose-limiting toxicity of OXL. Two types of neuropathy have been described with this agent: acute or transient and chronic or persistent, with different etiology, clinical manifestations and prognosis. This paper is an exhaustive review about the main aspects of oxaliplatin induced peripheral neuropathy, focus in clinical features, treatment, prevention strategies and future approach. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：166 / 178

页数：13

共 90 条

[61]

Markman Maurie, 2003, Expert Opin Drug Saf, V2, P597, DOI 10.1517/eods.2.6.597.21829

[62]

Marshall J, 2004, J CLIN ONCOL, V22, P3670

[63]

Morton RF, 2005, J CLIN ONCOL, V23, p750S

[64] Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater [J].

Overman, Michael J. ;

Varadhachary, Gauri R. ;

Kopetz, Scott ;

Adinin, Rosni ;

Lin, E. ;

Morris, Jeffrey S. ;

Eng, Cathy ;

Abbruzzese, James L. ;

Wolff, Robert A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2598-2603

[65] Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility [J].

Park, Susanna B. ;

Lin, Cindy S. Y. ;

Krishnan, Arun V. ;

Goldstein, David ;

Friedlander, Michael L. ;

Kiernan, Matthew C. .

ONCOLOGIST, 2011, 16 (05) :708-716

[66] Oxaliplatin-Induced Lhermitte's Phenomenon as a Manifestation of Severe Generalized Neurotoxicity [J].

Park, Susanna B. ;

Lin, Cindy S. -Y. ;

Krishnan, Arun V. ;

Goldstein, David ;

Friedlander, Michael L. ;

Kiernan, Matthew C. .

ONCOLOGY, 2009, 77 (06) :342-348

[67] Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy [J].

Park, Susanna B. ;

Lin, Cindy S. -Y. ;

Krishnan, Arun V. ;

Goldstein, David ;

Friedlander, Michael L. ;

Kiernan, Matthew C. .

BRAIN, 2009, 132 :2712-2723

[68] Oxaliplatin-related neurotoxicity: How and why? [J].

Pasetto, Lara Maria ;

D'Andrea, Mario Rosario ;

Rossi, Elena ;

Monfardini, Silvio .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 59 (02) :159-168

[69] Subcutaneous administration of amifostine: A promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy [J].

Penz, M ;

Kornek, GV ;

Raderer, M ;

Ulrich-Pur, H ;

Fiebiger, W ;

Scheithauer, W .

ANNALS OF ONCOLOGY, 2001, 12 (03) :421-422

[70] The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20 [J].

Postma, TJ ;

Aaronson, NK ;

Heimans, JJ ;

Muller, MJ ;

Hildebrand, JG ;

Delattre, JY ;

Hoang-Xuan, K ;

Lantri-Minet, M ;

Grant, R ;

Huddart, R ;

Moynihan, C ;

Maher, J ;

Lucey, R .

EUROPEAN JOURNAL OF CANCER, 2005, 41 (08) :1135-1139

← 1 2 3 4 5 6 7 8 9 →